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Abstract
Background: Temporary increases in plasma HIV RNA ('blips') are common in HIV patients on combination antiretroviral
therapy (cART). Blips above 500 copies/mL have been associated with subsequent viral rebound. It is not clear if this
relationship still holds when measurements are made using newer more sensitive assays.
Methods: We selected antiretroviral-naive patients that then recorded one or more episodes of viral suppression on
cART with HIV RNA measurements made using more sensitive assays (lower limit of detection below 50 copies/ml). We
estimated the association in these episodes between blip magnitude and the time to viral rebound.
Results: Four thousand ninety-four patients recorded a first episode of viral suppression on cART using more sensitive
assays; 1672 patients recorded at least one subsequent suppression episode. Most suppression episodes (87 %)
were recorded with TaqMan version 1 or 2 assays. Of the 2035 blips recorded, 84 %, 12 % and 4 % were of low
(50–199 copies/mL), medium (200–499 copies/mL) and high (500–999 copies/mL) magnitude respectively. The
risk of viral rebound increased as blip magnitude increased with hazard ratios of 1.20 (95 % CI 0.89-1.61), 1.42
(95 % CI 0.96-2.19) and 1.93 (95 % CI 1.24-3.01) for low, medium and high magnitude blips respectively; an
increase of hazard ratio 1.09 (95 % CI 1.03 to 1.15) per 100 copies/mL of HIV RNA.
Conclusions: With the more sensitive assays now commonly used for monitoring patients, blips above 200
copies/mL are increasingly likely to lead to viral rebound and should prompt a discussion about adherence.
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Background
Many patients with HIV start combination antiretroviral
therapy (cART), achieve a plasma HIV RNA ('viral load')
below the level of detection and then experience the oc-
casional 'blip'. A blip is 'a single, low-level but detectable
plasma viral load measurement (e.g., 50–1000 copies/mL)
that is immediately preceded and followed by a viral load
below the limit of detection' [1]. The clinical implications
of this transient detectable viremia are unclear. Early stud-
ies typically found no association between blips and subse-
quent viral rebound but were limited by their small
sample size (see Table 1 in [2]). However in a recent study
of 3550 patients, blips in excess of 500 copies/ml were
associated with an increased risk of viral rebound [2].
For more than a decade, the ultrasensitive Roche
Amplicor assay has been a standard method of measuring
HIV RNA in blood plasma when monitoring patients,
with a lower limit of detection of 50 copies/ml [3–6]. The
newer assays that have replaced it have lower limits of
detection below 50 copies/ml. A number of studies sug-
gest blip magnitudes are higher if measured with either
the Roche TaqMan version 1 or version 2 assays relative
to the Amplicor assay, although the Abbott RealTime
assay may give similar results [6–11]. This necessitates
a re-appraisal of the prognostic value of transient de-
tectable viremia.
The causes of transient detectable viremia are also un-
clear. Plausible explanations include the high variability
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of assays close to their lower limit of detection [12], re-
sidual low level viremia below the usual limit of detection
or a release of viral particles from replication in reservoirs
[13], vaccination or intercurrent viral infections [14, 15],
or less than full adherence to therapy [16]. It seems rea-
sonable to expect that there is no single explanation.
In this study, we consider whether blip magnitude –
the level of transient HIV RNA in blood plasma – is pre-
dictive of subsequent viral rebound using data from the
Swiss HIV Cohort Study (SHCS). We consider the effect
of different assays and of adherence on the predictive
value of transient detectable viremia in an effort to better
understand what a clinician ought to conclude when tran-
sient viremia is detected using these more sensitive assays.
Methods
Patient selection
The SHCS is a prospective cohort with continuing en-
rolment of HIV-infected adults [17]. Any HIV-infected
patient at least 18 years old can enrol in the SHCS. A
signed informed consent is required from all patients.
Data collection has been approved by an ethics committee
at each participating hospital (Ethikkommission beider
Basel, Kantonale Ethikkommission Bern, Comité départe-
mental d'éthique des spécialités médicales et de médecine
Genève, Commission cantonale d'éthique de la recherche
sur l'être humain Lausanne, Comitato etico cantonale
Bellinzona, Ethikkommission des Kantons St. Gallen,
Kantonale Ethikkommission Zürich [18]).
For this study, we selected all patients that were anti-
retroviral treatment naive before achieving viral suppres-
sion on their first cART regimen. We defined a first cART
regimen as the combination of any three or more anti-
retroviral drugs (except where all drugs were either nu-
cleoside or nucleotide reverse transcriptase inhibitors).
Most patients (95 %) in the SHCS received regimens
recommended in clinical guidelines [19]. During 2005
to 2009, the most common first regimens were efavirenz
with either tenofovir and emtricitabine or abacavir and
lamivudine; lopinavir (boosted with ritonavir) with either
tenofovir and emtricitabine or zidovudine and lamivudine;
or attazanavir (boosted with ritonavir), tenofovir and
emtricitabine [20].
We defined viral suppression as starting at the second
of two consecutive viral load measurements <50 copies/ml
where the two measurements were at least 30 days apart
and made using more sensitive assays. Viral suppression
began at the second of these two measurements because
our outcome – viral rebound – could not occur between
these two measurements [21]. Acceptable assays were
modified versions of the ultrasensitive Amplicor assay
[4, 22] (if the lower limit of detection was recorded and
below 50 copies/ml), the Abbott RealTime assay, and the
Roche TaqMan assay versions 1 and 2. These last three
assays have lower limits of detection of 40, 40 and 20
copies/ml respectively [6].
Suppression episodes
A suppression episode consisted of all viral load measure-
ments from the start of suppression until a last measure-
ment to date or until viral rebound, whichever came first.
Viral load is measured at cohort visits scheduled every six
months but intermediate measurements are also made so
that most patients are measured on average once every
three months. Patients could contribute more than one
suppression episode to our analyses if they again achieved
viral suppression after a viral rebound. Some patients con-
tributed a subsequent suppression episode (after a first
viral rebound) but did not have a first suppression episode
measured using acceptable assays. We defined viral re-
bound as the first of two consecutive viral load mea-
surements ≥50 copies/mL, where the two measurements
were at least 30 days apart, or a single viral load measure-
ment ≥1000 copies/mL [2]. We also considered an alter-
native definition of viral rebound – the first of two
consecutive viral load measurements ≥200 copies/mL
[23], where the two measurements were at least 30 days
apart, or a single viral load measurement ≥1000 copies/mL.
During each suppression episode, we recorded the
magnitude and number of blips. We defined a blip as a
viral load 50–999 copies/mL preceded and followed by
another measurement <50 copies/mL. Any subsequent
viral load measurement of 50–999 copies/mL within
30 days of a blip was considered to be part of the same
blip (although we updated the blip magnitude if a subse-
quent measurement was greater than its predecessor) [2].
Statistical methods
We fitted a variety of proportional hazard models to
data from first episodes and used these results to select
a suitable model for our analyses of both first and subse-
quent episodes (Additional file 1: Appendix A). A suitable
model should have separate baseline hazard functions for
both first and subsequent episodes because although the
effect of covariates may be the same in both first and sub-
sequent episodes, the rate of viral rebound is likely to be
higher in subsequent episodes (see Fig. 1). The selected
model was a generalised linear model for interval cen-
sored time to event data [24] with different strata for first
and subsequent episodes but we also fitted the gap-time
Cox model used in an earlier study [2]. The gap-time
model is a standard Cox model stratified by suppression
episode and with time reset to zero at the beginning of
each new episode (see [25]). However viral rebound is
interval censored because it is only known to have oc-
curred at some point between one measurement and the
next. The standard Cox model is known to underestimate
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hazard ratios when measurement error is added to event
times [26].
In our first analyses, blips were categorised by magnitude
as low (50–199 copies/mL), medium (200–499 copies/mL)
or high (500–999 copies/mL) [2]. Indicator variables were
used to represent these categories for the first blip per epi-
sode; these indicator values were set when a first blip oc-
curred and remained constant until the end of the episode.
In subsequent analyses, we represented blip magnitude by
a single continuous variable, scaled per 100 copies/mL. In
some analyses, this variable was updated to reflect the
magnitude of the latest blip in an episode (rather than the
first blip) or the cumulative value of blips in an episode to
date, or we added another time dependent variable repre-
senting the number of blips in the episode to date.
All analyses used the same set of covariates: gender,
injection drug use as the most likely mode of infection,
age at the beginning of the suppression episode, the year
the suppression episode began, the assay used to meas-
ure the blip, cART categories and CD4 cell count. These
last two covariates were updated whenever their values
changed within a suppression episode. We did not censor
patients if they stopped taking cART because such censor-
ing could be informative; rather we included a category
for 'no cART'. These covariates were all used in an earlier
study [2] except current CD4 cell count which we added
to our model because this is a strong predictor of HIV
progression even in patients with a suppressed viral load
[27]. CD4 cell count was represented by a linear spline
with a knot at 200 cells/μL and scaled per 100 cells/μL
[27]. To estimate the effect of covariates on the predictive
value of a blip, we added appropriate interaction terms to
our analyses (rather than carry out separate analyses for
different values of a covariate) [28].
All models were fit in SAS 9.3. Model parameters are
reported as the estimated hazard ratio (HR) and its 95 %
confidence interval (95 % CI).
Results
Study population
As at May 2014, 4094 antiretroviral naive patients in the
SHCS started treatment with a cART regimen and re-
corded a first episode of viral suppression using more sen-
sitive assays; 1672 of these patients later recorded a
subsequent episode of viral suppression on cART using
more sensitive assays. The median length of first and sub-
sequent suppression episodes was 2.9 [interquartile range,
IQR, 1.3 to 5.0] and 2.3 [IQR 1.0 to 4.7] years, respectively.
The median time between RNA measurements in first
and subsequent suppression episodes was 3.3 [IQR, 2.8 to
4.4] and 3.3 months [IQR 2.9 to 4.4], respectively. Most
suppression episodes (87 %) were recorded with TaqMan
version 1 or 2 assays (Table 1). Patients typically started a
first suppression episode with cART based on either a
boosted protease inhibitor (PI, 47 %) or a non-nucleoside
reverse transcriptase inhibitor (NNRTI, 42 %), but the lat-
ter was less common in subsequent episodes (30 %). The
rate of blips was 8.7 per 100 person years in first suppres-
sion episodes and 12.3 per 100 person years in subsequent
suppression episodes. The rate of viral rebound was 5.6
per 100 person years in first suppression episodes and
10.6 per 100 person years in subsequent suppression epi-
sodes. In first suppression episodes, 19 % of 785 rebounds
were preceded by a blip; in subsequent suppression epi-
sodes, 22 % of 695 rebounds were preceded by a blip.
Of the 2035 blips recorded, 84 %, 12 % and 4 % were
of low, medium and high magnitude respectively. The
time between a blip and the next viral load measurement
decreased with increasing blip magnitude: a median of 2.8,
1.9 and 1.5 months for low, medium and high magnitude
blips respectively. A change in cART between a blip and
the next viral load measurement was more likely as blip
magnitude increased: 2.4 %, 4.6 % and 6.1 % of low,
medium and high magnitude blips, respectively, were
followed by a change in cART class. Of the 57 changes in
cART class, common changes were from boosted PI based
therapy to either NNRTI (25 %) or entry or integrase
inhibitor (14 %) based therapy, or from NNRTI based
therapy to either boosted PI (9 %) or entry or integrase
inhibitor (11 %) based therapy.
Blip magnitude and subsequent viral rebound
When fit to first and subsequent episodes, both interval
censoring and gap-time Cox models suggest a gradual
increase in the risk of viral rebound with increasing blip
magnitude rather than a threshold effect (Table 2). Under
our model, estimates are: HR 1.20 (95 % CI 0.89 to 1.61),
HR 1.42 (95 % CI 0.96 to 2.19), HR 1.93 (95 % CI 1.24 to
3.01) for low, medium and high magnitude blips respect-
ively. Fitting these models to data from first episodes only
led to similar but less precise estimates (Additional file 1:
Appendix A). Replacing the three categories of blip mag-
nitude with a continuous variable makes it easier to test
whether the association between blip magnitude and viral
rebound varies with other factors. For example, the rela-
tive risk of viral rebound with increasing blip magnitude,
estimated in our model to be HR 1.09 (95 % CI 1.03 to
1.15) per 100 copies/mL of HIV RNA, was similar in
both first and subsequent suppression episodes (HR
1.11, 95 % CI 1.03 to 1.19, and HR 1.07, 95 % CI 1.00
to 1.15, per 100 copies/mL respectively). In the gap-
time model, the relative risk of viral rebound with in-
creasing blip magnitude was estimated to be HR 1.08
(95 % CI 1.03 to 1.14) per 100 copies/mL. Survival curves
show that this model simplification, from categories to a
continuous blip magnitude, did not materially alter the
predicted probabilities of viral rebound for a reference pa-
tient (Fig. 1). Note that while blip magnitude appears to
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have a similar association with viral rebound in both first
and subsequent suppression episodes, the baseline prob-
ability of viral rebound is greater in subsequent suppression
episodes than in first suppression episodes (Fig. 1). Using
an alternative definition of viral rebound – the first of two
consecutive viral load measurements ≥200 copies/mL or a
single viral load measurement ≥1000 copies/mL – reduced
the number of rebounds by 24 % to 600 in first suppression
episodes and by 40 % to 422 in subsequent suppression epi-
sodes. This attenuated HR estimates for blip magnitude cat-
egories and reduced their precision (Additional file 2:
Appendix B) but the estimate for a continuous variable
(HR 1.07, 95 % CI 1.01 to 1.13, per 100 copies/mL of
HIV RNA) suggests that even with this alternative defin-
ition, there is still a gradual increase in the risk of viral re-
bound with increasing blip magnitude.
Blip magnitude and assays
There was some evidence that viral rebound was associ-
ated with blips measured using the TaqMan version 2
assay relative to the Amplicor ultrasensitive assay (HR
1.31, 95 % CI 0.93 to 1.86, Table 2). However blip magni-
tude was not appreciably more predictive of viral rebound
with this assay than with other assays (HR 1.11, 95 % CI
0.97 to 1.26, per 100 copies/mL using the TaqMan version
2 assay, and HR 1.08, 95 % CI 1.02 to 1.15, per 100 copies/
mL using other assays). And low magnitude blips were not
appreciably less predictive of viral rebound with this assay
than with other assays, although this comparison lacks
power (HR 1.11, 95 % CI 0.60 to 2.04, using the TaqMan
version 2 assay, and HR 1.21, 95 % CI 0.90 to 1.63, using
other assays).
Blip magnitude and adherence
Routine collection of adherence data started in the SHCS
in May 2003. We defined non-adherent patients as those
who reported missing either two or more doses of an anti-
viral medication in a month [29]. In an analysis of data
collected after May 2003, the risk of viral rebound with in-
creasing blip magnitude was similar both in those report-
ing adherence and in those reporting non-adherence at
the time of the blip (HR 1.04, 95 % CI 0.94 to 1.15, and
HR 1.09, 95 % CI 0.93 to 1.27, per 100 copies/mL re-
spectively). However, in an analysis with time updated
non-adherence as a covariate, both reporting non-adherence
and not responding to questions on adherence were associ-
ated with a higher risk of viral rebound (HR 2.58, 95 % CI
2.07 to 3.22, and HR 1.51, 95 % CI 1.34 to 1.69, respectively).
In adherent patients, blip magnitude was predictive of
viral rebound (HR 1.13, 95 % CI 1.05 to 1.23, per 100
copies/mL); in non-adherent patients, it was not (HR
0.96, 95 % CI 0.80 to 1.17, per 100 copies/mL). The strong
association between non-adherence and viral rebound
(Fig. 2) is consistent with the strong association between
Table 1 Patient characteristics when starting a first suppression
episode or a first subsequent suppression episode. Patients had
to be antiretroviral treatment naive before achieving viral
suppression on a first combination antiretroviral regimen. Viral
suppression had to be recorded using a more sensitive assay:
ultrasensitive versions of the Amplicor assay (if the lower limit of
detection was recorded as <50 copies/ml), the Abbott RealTime
assay, and the TaqMan assay versions 1 and 2
Characteristic Suppression episode
First (4094
patients)
First subsequent (1672
patientsa)
Female (%) 27 34
Injection drug use (%)b 9 17
Age (median, years) 40 43
CD4 cell count (median, cells/
μL)
430 460
Year (%)
Before 2005 10 10
2005 to 2009 46 55
After 2009 45 35
Assay (%)c
Roche Amplicor ultrasensitive 12 14
Abbot RealTime 1 1
Roche TaqMan version 1 37 45
Roche TaqMan version 2 50 41
cART class (%)
NNRTI 42 31
Boosted PI 47 47
Single PI 4 7
Entry or integrase inhibitor 4 7
Otherd 3 7
Magnitude of first blip (%)
No blips 78 72
Low (50–199 copies/mL) 19 23
Medium (200–499 copies/mL) 2 4
High (500–999 copies/mL) 1 2
Number of blips (%)
None 78 72
One 16 20
Two 4 6
Three or more 2 2
Viral rebound (%) 19 33
cART combination antiretroviral therapy; NNRTI non-nucleoside reverse
transcriptase inhibitor; PI protease inhibitor
aPatients that had a subsequent suppression episode measured using
acceptable assays did not always have a first suppression episode measured
using acceptable assays
bInjection drug use as the most likely mode of HIV infection
cFirst use of each assay in these data: Roche Amplicor ultrasensitive, 1997;
Abbot RealTime, 2009; Roche TaqMan version 1, 2002; Roche TaqMan
version 2, 2006. Common use of each assay in these data (10th to 90th
percentiles): Roche Amplicor ultrasensitive, 2000–05; Abbot RealTime, 2009–12;
Roche TaqMan version 1, 2006–09; Roche TaqMan version 2, 2009–13 (current)
dOther: More than one PI (other than ritonavir), a PI and an NNRTI, or three
nucleoside or nucleotide reverse transcriptase inhibitors. The later was
considered cART only if it followed an earlier cART regimen
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stopping cART and viral rebound (HR 10.6, 95 % CI 8.17
to 13.7, Table 2).
More than one blip per suppression episode
In first suppression episodes, 6 % of patients had more
than one blip; in subsequent suppression episodes, 8 %
of patients had more than one blip (Table 1). The mag-
nitude of the first blip in a suppression episode was as
predictive of viral rebound (HR 1.09, 95 % CI 1.03 to
1.15, per 100 copies/mL) as the magnitude of the most
recent blip or the cumulative magnitude of blips during
an episode (HR 1.10, 95 % CI 1.04 to 1.16, and HR 1.10,
95 % CI 1.06 to 1.14, per 100 copies/mL respectively).
However the risk of viral rebound increased with both
the magnitude of the first blip and the number of blips
per suppression episode (HR 1.28, 95 % CI 1.12 to 1.45,
per blip).
Discussion
Earlier conclusions based on RNA measurements made
using Amplicor ultrasensitive and bDNA assays [2] seem
to broadly apply to our data where most RNA measure-
ments were made with TaqMan version 1 or 2 assays.
We use definitions and methods consistent with this
earlier study so results can be directly compared. How-
ever our data show a gradual increase in the relative risk
of viral rebound with increasing blip magnitude (HR 1.09,
95 % CI 1.03 to 1.15, per 100 copies/mL of HIV RNA), ra-
ther than a threshold effect. The threshold of 500 copies/mL
suggested by this earlier study [2] corresponds to an es-
timated hazard ratio of nearly 2 in our data but a lower
threshold of 200 copies/mL still leads to an increase in
relative risk with an estimated hazard ratio of nearly 1.5.
Agreement between more sensitive assays is poor below
200 copies/mL [6, 12]. A number of studies have shown
that blip magnitudes are higher if measured with either
the TaqMan version 1 or version 2 assays relative to the
Amplicor assay [7–10]. This has led to the suggestion that
with more sensitive assays, 100 to 200 copies/mL might
be a more appropriate threshold for concern than 50
copies/mL [8, 9] and guidelines now define virologic
Fig. 1 Survival curves with first blip magnitude either in categories (left) or as a continuous measure (right) [24]. Curves are shown for the first
suppression episode (top) and for subsequent suppression episodes (bottom). All curves are for the same reference patient: a male who did not
acquire HIV though injection drug use, starting a suppression episode in 2005 at the age of 40, on a non-nucleoside reverse transcriptase based
regimen, with a CD4 cell count of 350 cells/μL and with HIV RNA measured using an Amplicor ultrasensitive assay
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failure as a persistent plasma RNA of 200 copies/mL or
more [23].
Our analyses lack the power to precisely estimate indi-
vidual associations between blip magnitude and viral re-
bound for each assay. It is reasonable to expect that low
magnitude blips will be less predictive of viral rebound
when made with a TaqMan version 2 assay given reports
that more low magnitude blips are detected with this assay
[6, 9–11]. Our estimates are consistent with this expect-
ation but are too imprecise to be definitive. The increased
sensitivity of the TaqMan version 2 assay, however, does
not seem material in these data, in contrast to studies
suggesting such effects might be important [9, 10], be-
cause blip magnitudes measured with this assay were
not dramatically more or less predictive of viral rebound
than blip magnitudes measured with other assays.
It is important to distinguish between transient viremia
and persistent low level viremia [30]. Recent studies in
SHCS and other data show that persistent low level
viremia, typically defined as two or more consecutive
detectable viral load measurements below 1000 copies/
mL, is associated with an increased risk of virologic failure
[31–33]. Even persistent viremia below 50 copies/mL may
increase the risk of viral rebound [34]. In our data, the
time between a blip and the next viral load measurement
decreased with increasing blip magnitude and this sug-
gests clinicians were responding appropriately to low but
detectable measurements to determine whether such
measurements were the first sign of virologic failure.
Persistent low level viremia becomes an event in these
analyses through our definition of viral rebound. While
it is possible that blips are a precursor to persistent
low-level viremia [1], blips typically do not lead to drug
resistance [8, 9, 16, 35].
Our results are consistent with the hypothesis that the
association between blip magnitude and viral rebound
largely arises through periodic non-adherence [16, 36, 37].
First, where a patient was known to be non-adherent,
knowledge of blip magnitude was then redundant (Fig. 2).
Second, the magnitude of the first blip in a suppression
episode was no less predictive of subsequent viral rebound
than either the magnitude of the most recent blip in an
episode or the cumulative magnitude of blips in an epi-
sode; yet the number of blips in the episode was addition-
ally predictive of viral rebound. The lack of evidence
either for a stronger effect with updated measurements
[38] or for a stronger cumulative effect [39] is consistent
with blips being a marker for periodic non-adherence ra-
ther than due to random variation in residual viral replica-
tion below the usual limit of detection [13, 40]. That is, in
these data the amount of replication during a suppression
episode seems less important than whether there was
replication or not. The increasing risk of rebound with
increasing blip magnitude might represent a probabilistic
separation between residual replication below 10 copies/
mL [40, 41] found in many suppressed patients and spor-
adically detected and over-estimated by more sensitive as-
says, in particular, the TaqMan version 2 [11, 12], and
replication resulting from non-adherence, with the latter
Table 2 Estimates of associations between covariates and
subsequent viral rebound in models fit to data from both first
and subsequent suppression episodes
Covariate Hazard ratio (95 % confidence
interval)
Model for interval
censored data [24]
Gap-time Cox
model [2]
Magnitude of first blip (reference no blips)
Low (50–199 copies/mL) 1.20 (0.89, 1.61) 1.03 (0.77, 1.38)
Medium (200–499 copies/mL) 1.42 (0.96, 2.19) 1.25 (0.86, 1.82)
High (500–999 copies/mL) 1.93 (1.24, 3.01) 1.69 (1.10, 2.60)
Female 1.16 (1.03, 1.30) 1.12 (1.00, 1.25)
Injection drug usea 1.21 (1.04, 1.41) 1.25 (1.08, 1.45)
Age (per 10 years) 0.91 (0.86, 0.97) 0.89 (0.84, 0.95)
Calendar year episode began
(per year)
0.92 (0.90, 0.94) 0.93 (0.91, 0.95)
Assay (reference Roche Amplicor ultrasensitive)
Abbot RealTime 2.19 (0.65, 7.41) 2.46 (0.81, 7.47)
Roche TaqMan version 1 0.90 (0.65, 1.25) 0.87 (0.63, 1.19)
Roche TaqMan version 2 1.31 (0.93, 1.86) 1.23 (0.88, 1.72)
cART regimen (reference NNRTI based)
Boosted PI 1.85 (1.62, 2.10) 1.76 (1.55, 2.01)
Single PIb 1.73 (1.39, 2.16) 1.68 (1.35, 2.09
Entry or integrase inhibitorc 1.98 (1.63, 2.41) 1.77 (1.45, 2.15)
Noned 10.6 (8.17, 13.7) 8.70 (6.87, 11.0)
CD4 cell count (per 100 cells/μL)e
0 to <200 0.74 (0.57, 0.97) na
≥ 200 1.01 (0.98, 1.03) na
RNA tests per year (reference >6)e
≤ 3 na 0.31 (0.23, 0.42)
3-≤ 4 na 0.36 (0.27, 0.48)
4-≤ 6 na 0.47 (0.27, 0.48)
cART combination antiretroviral therapy; NNRTI non-nucleoside reverse
transcriptase inhibitor; PI protease inhibitor; na not applicable
aInjection drug use as the most likely mode of HIV infection
bAlso includes regimens with three nucleoside or nucleotide reverse
transcriptase inhibitors - such regimens were considered cART if they followed
another earlier cART regimen
cAlso includes regimens with more than one PI (other than ritonavir), or with a
PI and an NNRTI - all these regimens were mostly used as salvage regimens
during this era
dThe cART regimen was updated whenever its value changed within a
suppression episodes. A patient not on cART was highly likely to experience
viral rebound
eThe gap-time Cox model in [2] has the number of RNA tests per year as a
covariate but not CD4 cell count. The number of RNA tests per year is not an
appropriate covariate in models for interval censored data – see, Additional file 1:
Appendix A. Current (time updated) CD4 cell count was added to the model for
interval censored data because it is a strong predictor of HIV progression even in
patients with a suppressed viral load [27]
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much more likely to be associated with viral rebound than
the former.
Viral rebound was also more likely in females, in
younger patients and in those infected through injection
drug use – as in an earlier study [2]. Increases in CD4
cell count were associated with a lower risk of viral re-
bound but only while patients had a CD4 cell count
below 200 cells/μL, consistent with other studies where
a CD4 cell count of 200 cells/μL proved to be an import-
ant threshold [27]. Viral rebound was more likely with
the use of either boosted PI based cART or entry or
integrase inhibitor based cART. When these data were
collected, such regimens were typically prescribed to pa-
tients thought more prone to non-adherence or to patients
who had experienced virologic failure on other regimens.
However viral rebound was both more likely with the use
of single PI cART and less likely with increasing calendar
time and this suggests that newer regimens have reduced
the risk of viral rebound.
The strengths of this study are data collected with
more sensitive assays and data on reported adherence
to cART, the use of statistical models appropriate for
interval censored time to event data and the combin-
ing of data from first and subsequent suppression epi-
sodes (given that it seems appropriate to do so).
Limitations include a lack of power to estimate assay
specific associations — in particularly, there was little
use of Abbott RealTime assay — and we expect there
will be some differences between more sensitive assays
in the predictive value of increasing blip magnitude
[42]. Self-reported adherence overestimates adherence
but there is a strong association between self-reported
adherence and virological outcomes [29, 43]. Misclassi-
fication of non-adherent patients as adherent could lead to
an underestimate of the association between non-adherence
and viral rebound but is unlikely to result in residual
confounding in the association between blip magnitude
and viral rebound because adjustment for time dependent
Fig. 2 Survival curves given a patient reporting either complete adherence to antiretroviral therapy (left) or non-adherence to antiretroviral therapy
(right) [24]. Curves are shown for the first suppression episode (top) and for subsequent suppression episodes (bottom). All curves are for the same
reference patient: a male who did not acquire HIV though injection drug use, starting a suppression episode in 2005 at the age of 40, on a
non-nucleoside reverse transcriptase based regimen, with a CD4 cell count of 350 cells/μL and with HIV RNA measured using an Amplicor
ultrasensitive assay
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non-adherence did not change the point estimate for the
effect of blip magnitude (from HR 1.09, 95 % CI 1.03 to
1.15, to HR 1.09, 95 % CI 1.01 to 1.18 per 100 copies/mL
of HIV RNA) [44, 45]. We did not consider the frequency
of blips, and we expect that blips are more likely both with
more sensitive assays and with more intensive RNA moni-
toring in patients with a higher risk of disease progression
[2]. In this study we focus on what clinicians ought to
conclude when they detect a blip with the more sensitive
assays now commonly used for monitoring patients.
Conclusion
Taken together, this and other recent studies suggest that
with more sensitive assays, blips in excess of 200 copies/
mL are increasingly likely to be due to non-adherence, ra-
ther than due to either random variation in residual
viremia or assay measurement error, and are therefore a
reason for clinicians to discuss adherence with their
patients.
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